I agree and previously posted that, even if SPPI manages to obtain regulatory approval, another non-substitutable Rituxan knockoff in the US market is apt to be a commercial bust. I highly doubt that SPPI and its partner have the technological prowess to get the FDA to designate their Rituxan knockoff as substitutable for the branded product.
This SPPI rituxan FOB thing seems like a terrible idea for them and way out of their league. Strikes me as an ego thing for the company and its management to be involved in the arena. They don't have the money or expertise to play the game
This foray for SPPI reminds me of its short-lived strategy to develop Indian generic drugs as a way to fund its once promising drug, satraplatin.
Market Data 
Markets 
AI
